Cesarean delivery is among the most frequently performed surgeries in the world. Alongside its familiarity, the procedure carries surgical considerations that merit ongoing attention, including wound healing, recovery experience, and postoperative complications. These realities invite continued reflection on how care at the moment of closure can support both short-term recovery and longer-term maternal well-being.
Recibio, Inc., a Houston-based medical technology company, approaches this landscape with thoughtful acknowledgment of those considerations. Through its work, the company champions the use of a mother’s own amniotic fluid during cesarean wound closure as part of the standard of care, with the intent of supporting wound healing and influencing adhesion formation in a biologically aligned way.
“From what we’re seeing, even small steps forward in wound care could have a meaningful influence on mothers, newborns, and the systems that support them,” Geoffrey Jones, founder of Recibio, says. Within this context, Recibio’s insights center on how naturally available biological materials, already present during surgery, may be thoughtfully reintegrated into care pathways.
Amniotic tissue and fluid have drawn sustained interest across regenerative medicine for their distinctive biological properties, demonstrating useful characteristics that modulate inflammation, provide microbial defense, and resist tissue adhesion for improved wound healing.
Research on amniotic-derived materials describes their broad differentiation potential and immunologically compatible profile, qualities that have informed exploration across skin, musculoskeletal, and organ-related applications. This body of work suggests that amniotic fluid offers a supportive biological environment for healing, one that mirrors processes familiar from fetal development while remaining suitable for adult tissues.
Recibio’s CeaLogic product line emerges from this scientific foundation with a focused clinical application. Designed specifically for women undergoing cesarean delivery, CeaLogic products enable the collection and immediate reapplication of autologous amniotic fluid at the time of surgery. “Basically, we’re taking something from the mother that would normally be donated or discarded and using it to support her healing,” Jones explains. “As it relies on the patient’s own amniotic fluid, there is zero chance of rejection, and it easily fits into standard surgical practice.”
The mechanism guiding this approach focuses on leveraging cells and bioactive components already present in amniotic fluid. These elements are understood to participate in tissue signaling, inflammation modulation, and antimicrobial activity, creating conditions that may support repair while preventing scar formation.
Research supported by Recibio adds clinical nuance to this understanding. In the study titled The Collection and Application of Autologous Amniotic Fluid to Cesarean Delivery Closure, investigators demonstrated that amniotic fluid could be successfully collected and reapplied during closure using the CeaLogic system. Jones states, “Over the six‑week follow‑up, participants reported consistently lower pain scores and no wound complications or infections. To me, that really shows how feasible and reliable this approach is in everyday clinical practice.” The study emphasized the need for continued research while underscoring the promise of this biologically informed technique.
Complementing these findings, a prospective clinical registry initiative at UTHealth Houston explores autologous amniotic fluid as an antimicrobial adjunct during cesarean delivery. According to the registry proposal, amniotic fluid contains defensins, lactoferrin, and other peptides associated with antimicrobial activity, alongside properties that support epithelialization and comfort during healing. By documenting outcomes such as wound appearance, patient experience, and adverse events, the registry aims to build real-world evidence around how this approach may function alongside existing prophylactic practices as part of the standard of care.
For patients, the implications extend beyond clinical metrics. “Birth is already an intense moment. If we can support healing in a way that feels intuitive to the body, we offer mothers a path through recovery,” Jones remarks. Recibio’s perspective frames the use of autologous amniotic fluid as a way to support less pain, greater comfort, and a sense of reassurance that healing draws from one’s own biology.
Scalability remains central to this vision. Cesarean deliveries often occur in regions where access to follow-up care varies widely. Recibio positions CeaLogic as adaptable across any environment where the surgery takes place, from high-volume urban facilities to hospitals serving geographically isolated communities. “Because the system relies on materials already present during surgery and integrates into established procedures, implementation can feel more familiar,” Jones states. This practicality supports broader adoption, including in settings where infection risk carries heightened consequences and resources may be constrained.
“Our hope is that every mother, regardless of where she delivers, receives the same thoughtful support at closure,” Jones shares. “Using her own amniotic fluid honors the biology of birth and invites healing to continue naturally.” In this future, CeaLogic becomes embedded in routine practice, recognized globally as a standard of care for cesarean delivery.
As cesarean rates continue to influence obstetric landscapes worldwide, attention to healing at the moment of closure gains renewed significance. Through research-supported exploration, biologically aligned design, and a focus on patient experience, Recibio contributes a humane perspective to this conversation. The result is an evolving model of care that invites collaboration and thoughtful integration into the places where mothers and clinicians meet at one of life’s most meaningful thresholds.
